Hospital
Methodist Healthcare - Memphis Hospitals
Methodist Healthcare - Memphis Hospitals was paid $84.41M by Medicaid between Jan 2018 and Dec 2024, across 270 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoMETHODIST HEALTHCARE - MEMPHIS HOSPITALS
MEMPHIS, TN 38103
MEMPHIS, TN 38103
33aNPI1386709871assigned 12/26/2006
33bProvider typeChildren's Hospital
28Total paid$84.41M
24GClaims1,133,794
24DCodes billed270
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 164,261 | $8.93M | |
| 2019 | 147,155 | $12.25M | |
| 2020 | 139,530 | $10.61M | |
| 2021 | 178,478 | $13.19M | |
| 2022 | 222,030 | $14.25M | |
| 2023 | 158,771 | $14.42M | |
| 2024incomplete | 123,569 | $10.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 131,828 | 123,281 | $21.26M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 51,425 | 47,314 | $13.62M |
| G0378 | Hospital observation service, per hour | 7.7% | 11,311 | 7,909 | $6.54M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.1% | 74,088 | 71,003 | $5.13M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.7% | 36,674 | 36,094 | $4.78M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.6% | 6,180 | 5,896 | $3.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.9% | 9,491 | 6,927 | $2.47M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.8% | 1,050 | 977 | $2.37M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.1% | 41,412 | 38,343 | $1.78M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 19,432 | 18,319 | $1.53M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.8% | 1,534 | 1,196 | $1.51M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.6% | 17,071 | 16,462 | $1.34M |
258 more codes
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.4% | 3,302 | $1.18M |
| 92587 | 1.2% | 8,535 | $994K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 29,777 | $974K |
| 54161 | <1% | 888 | $797K | |
| 92567 | <1% | 21,508 | $676K | |
| 93304 | <1% | 2,418 | $658K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,796 | $647K |
| 87400 | <1% | 45,447 | $634K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,452 | $618K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14,595 | $542K |
| 92579 | <1% | 5,979 | $430K | |
| 95812 | <1% | 2,921 | $412K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,050 | $405K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,117 | $376K |
| 36415 | Collection of venous blood by venipuncture | <1% | 73,150 | $371K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,162 | $371K |
| 29705 | <1% | 3,038 | $362K | |
| 76770 | <1% | 4,252 | $348K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,884 | $336K |
| 93325 | <1% | 11,838 | $316K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 462 | $308K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,097 | $287K |
| 64430 | <1% | 752 | $237K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,531 | $227K |
| 94010 | <1% | 2,431 | $220K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 624 | $214K |
| 74230 | <1% | 2,270 | $207K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,445 | $206K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,826 | $194K |
| 74018 | <1% | 3,123 | $194K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 794 | $192K |
| 80053 | Comprehensive metabolic panel | <1% | 26,486 | $187K |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,649 | $173K |
| 72082 | <1% | 2,458 | $168K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 244 | $164K |
| 74019 | <1% | 4,083 | $163K | |
| 72170 | <1% | 2,628 | $160K | |
| 93320 | <1% | 3,402 | $151K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14,335 | $151K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,601 | $145K |
| 92557 | <1% | 1,538 | $143K | |
| 87807 | <1% | 14,817 | $139K | |
| 92611 | <1% | 2,235 | $122K | |
| 73070 | <1% | 2,161 | $119K | |
| 73110 | <1% | 2,301 | $119K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,134 | $118K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,407 | $110K |
| 42830 | <1% | 87 | $108K | |
| 73090 | <1% | 2,334 | $103K | |
| 70360 | <1% | 1,898 | $101K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,240 | $96K |
| 92582 | <1% | 1,010 | $91K | |
| 97161 | <1% | 1,834 | $90K | |
| 73590 | <1% | 1,733 | $85K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,083 | $69K |
| 93321 | <1% | 3,609 | $68K | |
| 54360 | <1% | 47 | $64K | |
| 73552 | <1% | 1,299 | $63K | |
| 92555 | <1% | 1,781 | $60K | |
| 73610 | <1% | 1,105 | $59K | |
| 86900 | <1% | 1,085 | $57K | |
| 73630 | <1% | 988 | $55K | |
| 82570 | <1% | 5,518 | $55K | |
| 84439 | <1% | 5,305 | $52K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,662 | $51K |
| 73130 | <1% | 1,003 | $50K | |
| 93308 | <1% | 321 | $48K | |
| 73560 | <1% | 867 | $47K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 170 | $46K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 592 | $39K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,523 | $39K |
| 86140 | <1% | 9,605 | $38K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 375 | $37K |
| 82610 | <1% | 2,235 | $35K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 649 | $34K |
| 80061 | Lipid panel | <1% | 2,363 | $33K |
| 92552 | <1% | 583 | $31K | |
| 82803 | <1% | 2,175 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 708 | $30K |
| 95782 | <1% | 28 | $29K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 668 | $25K |
| 86850 | <1% | 1,038 | $25K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 344 | $24K |
| 54300 | <1% | 12 | $24K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,038 | $24K |
| 75561 | <1% | 24 | $21K | |
| 83970 | <1% | 711 | $20K | |
| 29065 | <1% | 128 | $19K | |
| 82784 | <1% | 1,639 | $18K | |
| 86901 | <1% | 1,085 | $18K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 86 | $17K |
| 31571 | <1% | 12 | $17K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 48 | $17K |
| 85652 | <1% | 5,796 | $17K | |
| 81025 | <1% | 3,523 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,136 | $16K |
| 80069 | <1% | 1,825 | $16K | |
| 80197 | <1% | 1,272 | $15K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 384 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,952 | $15K |
| 82043 | <1% | 2,265 | $14K | |
| 83735 | <1% | 2,332 | $14K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 197 | $14K |
| 87186 | <1% | 1,762 | $13K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 128 | $13K |
| 82565 | <1% | 1,011 | $12K | |
| 87070 | <1% | 2,103 | $12K | |
| 82728 | <1% | 1,217 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 21,204 | $11K |
| 81001 | <1% | 6,546 | $11K | |
| 83880 | <1% | 387 | $11K | |
| 87040 | <1% | 1,799 | $11K | |
| 81003 | <1% | 6,617 | $11K | |
| 14040 | <1% | 26 | $10K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,328 | $10K |
| 84100 | <1% | 2,649 | $9K | |
| 87077 | <1% | 1,329 | $9K | |
| 85730 | <1% | 2,388 | $9K | |
| 76825 | <1% | 15 | $9K | |
| 85610 | <1% | 3,280 | $9K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 27 | $8K |
| 76820 | <1% | 65 | $8K | |
| 82330 | <1% | 924 | $8K | |
| 84156 | <1% | 2,415 | $8K | |
| 82977 | <1% | 960 | $8K | |
| 84466 | <1% | 892 | $8K | |
| 83690 | <1% | 1,915 | $8K | |
| 82657 | <1% | 292 | $7K | |
| 76821 | <1% | 49 | $7K | |
| 92610 | <1% | 142 | $7K | |
| 83516 | <1% | 614 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,396 | $6K |
| 83540 | <1% | 1,389 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 25,543 | $6K |
| 97802 | <1% | 1,804 | $6K | |
| 85027 | <1% | 964 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 347 | $6K |
| 88342 | <1% | 86 | $6K | |
| 97165 | <1% | 100 | $5K | |
| 82150 | <1% | 1,382 | $5K | |
| 64450 | <1% | 26 | $5K | |
| 87081 | <1% | 1,040 | $5K | |
| 87205 | <1% | 1,641 | $5K | |
| 92556 | <1% | 97 | $5K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 950 | $4K |
| 82962 | <1% | 1,726 | $4K | |
| 97803 | <1% | 1,344 | $4K | |
| 77073 | <1% | 65 | $4K | |
| 83605 | <1% | 525 | $4K | |
| 86364 | <1% | 794 | $4K | |
| 93226 | <1% | 102 | $4K | |
| 80177 | <1% | 320 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 353 | $3K |
| 92593 | <1% | 69 | $3K | |
| 83935 | <1% | 350 | $3K | |
| 84460 | <1% | 329 | $3K | |
| 84132 | <1% | 958 | $2K | |
| 73060 | <1% | 48 | $2K | |
| 84295 | <1% | 867 | $2K | |
| 92583 | <1% | 54 | $2K | |
| 76827 | <1% | 28 | $2K | |
| 77072 | <1% | 26 | $2K | |
| 29345 | <1% | 18 | $2K | |
| 74240 | <1% | 12 | $2K | |
| 82947 | <1% | 228 | $2K | |
| 83655 | <1% | 44 | $2K | |
| 87147 | <1% | 326 | $2K | |
| 94060 | <1% | 13 | $2K | |
| 92523 | <1% | 13 | $2K | |
| 76000 | <1% | 18 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 59 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 59 | $2K |
| 85014 | <1% | 759 | $1K | |
| 93225 | <1% | 15 | $1K | |
| 36416 | <1% | 634 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 12 | $1K |
| 87634 | <1% | 64 | $1K | |
| 94664 | <1% | 117 | $1K | |
| 92626 | <1% | 13 | $1K | |
| 96415 | <1% | 28 | $1K | |
| 84300 | <1% | 172 | $1K | |
| 94761 | <1% | 81 | $1K | |
| 97162 | <1% | 19 | $1K | |
| 84520 | <1% | 135 | $1K | |
| 86160 | <1% | 77 | $863.55 | |
| 92595 | <1% | 26 | $857.06 | |
| 90686 | <1% | 92 | $843.05 | |
| 85018 | <1% | 308 | $766.24 | |
| 82550 | <1% | 136 | $661.83 | |
| 83615 | <1% | 166 | $648.91 | |
| 75565 | <1% | 12 | $584.46 | |
| 76376 | <1% | 1,285 | $513.54 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 25 | $484.66 |
| 82040 | <1% | 84 | $482.04 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,853 | $454.30 |
| 92650 | <1% | 33 | $453.81 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17 | $448.07 |
| 80235 | <1% | 16 | $419.31 | |
| 84484 | <1% | 47 | $406.73 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,292 | $392.70 |
| 87799 | <1% | 18 | $347.04 | |
| 87497 | <1% | 15 | $347.04 | |
| 87102 | <1% | 51 | $304.86 | |
| 83519 | <1% | 17 | $284.77 | |
| 84436 | <1% | 24 | $274.58 | |
| 82542 | <1% | 23 | $262.82 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,134 | $254.63 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15,151 | $249.00 |
| 86225 | <1% | 16 | $203.46 | |
| 84550 | <1% | 71 | $198.40 | |
| 82785 | <1% | 16 | $195.24 | |
| 86038 | <1% | 20 | $190.86 | |
| 83520 | <1% | 14 | $170.94 | |
| 80203 | <1% | 18 | $155.86 | |
| C1769 | Guide wire | <1% | 467 | $151.83 |
| 80164 | <1% | 15 | $134.09 | |
| 94760 | <1% | 14 | $127.26 | |
| 87184 | <1% | 16 | $100.95 | |
| 84133 | <1% | 14 | $96.60 | |
| C1733 | Catheter, electrophysiology, diagnostic/ablation, other than 3d or vector mapping, other than cool-tip | <1% | 5,963 | $90.63 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,578 | $89.87 |
| 83525 | <1% | 64 | $85.60 | |
| 86592 | <1% | 30 | $77.76 | |
| 84703 | <1% | 14 | $74.17 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,203 | $68.82 |
| 82272 | <1% | 14 | $67.30 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 98 | $59.40 |
| 99152 | <1% | 538 | $55.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 391 | $51.71 |
| 85045 | <1% | 20 | $43.08 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,094 | $42.78 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 577 | $30.46 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 572 | $21.10 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 186 | $20.14 |
| J3490 | Unclassified drugs | <1% | 493 | $12.95 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 975 | $8.15 |
| A4649 | Surgical supply; miscellaneous | <1% | 187 | $6.62 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 1,699 | $4.36 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 54 | $2.98 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 22 | $1.46 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 157 | $0.60 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 173 | $0.26 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 138 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 181 | $0.00 |
| Q4007 | Cast supplies, long arm cast, pediatric (0-10 years), plaster | 0% | 31 | $0.00 |
| V5275 | Ear impression, each | 0% | 13 | $0.00 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 49 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 13 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 66 | $0.00 |
| 84145 | 0% | 651 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 36 | $0.00 |
| 87631 | 0% | 20 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 38 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 36 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 172 | $0.00 |
| 0223U | 0% | 91 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 107 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCLEAN, CHRIS (CHIEF FINANCIAL OFFICER)
Parent organizationMETHODIST LE BONHEUR HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Methodist Healthcare - Memphis Hospitals | Germantown, TN | $3.32M |
| Methodist Healthcare - Memphis Hospitals | Memphis, TN | $15K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.